Yige Bao, Oncological Urologist and Microbiome researcher in West China Hospital, shared a post on X:
“Exciting news! Our data from the high-risk UTUC nephron-sparing trial has been accepted at ESMO 2024 (European Society for Medical Oncology Congress 2024)! Demonstrating the potential to preserve kidneys in carefully selected high-risk UTUC patients.”
Source: Yige Bao/X